ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Oncology and Hematology News and Journal Articles

New Treatment Options and Management Considerations in Borderline Resectable Pancreatic Cancer

In this article we will discuss the definitions of resectability, describe the current diagnostic tests for pancreatic cancer, and review strategies for maximizing treatment outcomes in patients with resectable pancreatic cancer.

Recent Content

Limiting Medicaid enrollment has the potential for negative health impacts, in particular among low-income women with a diagnosis of breast cancer, according to a new study.

A 57-year-old man presents with hematuria, and a bladder biopsy is obtained. What is your diagnosis?

A biosimilar to trastuzumab known as CT-P6 showed equivalent efficacy and similar toxicity to the original agent in patients with HER2-positive breast cancer.

The addition of two cycles of neoadjuvant chemotherapy to concurrent chemoradiotherapy improved tumor control in patients with nasopharyngeal carcinoma.

Treatment with single-agent bevacizumab resulted in an improved disease-free interval in patients with resected melanoma, but no increase in overall survival compared with observation.

The primary tumor location was an independent prognostic marker in patients with RAS wild-type metastatic colorectal cancer after multivariable adjustment.

This slide show highlights some of this year’s FDA approvals of cancer treatments, including new therapies and indications for breast cancer, lung cancer, and various blood cancers, as well as the first approval based not on disease site but rather by a tumor marker.

By clicking Accept, you agree to become a member of the UBM Medica Community.